Cholangiocarcinoma, Intrahepatic Clinical Trial
Official title:
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Verified date | January 2020 |
Source | Halozyme Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
Status | Terminated |
Enrollment | 85 |
Est. completion date | November 11, 2019 |
Est. primary completion date | November 11, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: For both portions of the study, participants must satisfy all of the following inclusion criteria to be enrolled in the study: - Written Institutional Review Board/Ethics Committee-approved informed consent form (ICF), signed by participant or legally authorized representative. - Participants must be determined to have histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the intra- and/or extra-hepatic bile ducts and/or gallbladder. Participants must have sufficient tissue with architectural integrity, including tumor and associated stroma, available for retrospective biomarker testing. - One or more lesions measurable on computed tomography (CT) scan/magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). - Participants having Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. - Life expectancy =3 months. - Males and females aged =18 years. - Screening clinical laboratory values within pre-determined parameters - Female participants of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days before Day 1 (first dose of study medication). - For WOCBP and for men, agreement to use a highly effective contraceptive method from the time of screening throughout the study until 5 months (WOCBP) or 6 months (men) after administration of the last dose of any study medication. Highly effective contraceptive methods consist of prior sterilization, intrauterine device (IUD), intrauterine hormone releasing system (IUS), oral or injectable contraceptives, barrier methods, and/or true sexual abstinence. Exclusion Criteria: Participants are ineligible for enrollment if they meet any of the following exclusion criteria: - Clinical evidence of deep vein thrombosis or pulmonary embolism present during the screening period - New York Heart Association Class III or IV cardiac disease, atrial fibrillation, unstable angina, or myocardial infarction within the past 12 months before screening. - Participants with known brain metastases - History of cerebrovascular accident or transient ischemic attack - History of active bleeding within the last 3 months prior to screening requiring transfusion. - Participants must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for treatment of metastatic or locally advanced disease. - Intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). - Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface antigen (HBsAg) test at screening - Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at screening - History of: 1. Idiopathic pulmonary fibrosis, organizing pneumonia (for example, bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted. 2. Or known cases of hepatobiliary diseases (for example, primary biliary cholangitis, primary sclerosing cholangitis, history of immune-mediated cholangitis); Participants with cholangitis attributed to infectious etiology (for example, ascending cholangitis, bacterial cholangitis) are eligible if the infection has been fully resolved prior to the screening visit. 3. Or known cases of drug-induced hepatobiliary toxicities. - Active or history of autoimmune diseases - Uncontrolled hypercalcemia |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | Gyeonggi-do |
Korea, Republic of | Asan Medical Center | Seoul | Songpa-gu |
Korea, Republic of | Korea University Guro Hospital | Seoul | Guro-gu |
Korea, Republic of | Samsung Medical Center | Seoul | Gangnam-gu |
Korea, Republic of | Seoul National University Hospital | Seoul | Jongno-gu |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | Seodaemun-Gu |
Korea, Republic of | The Catholic University of Korea Seoul St. Mary's Hospital | Seoul | Seocho-gu |
Thailand | King Chulalongkorn Memorial Hospital | Bangkok | Patumwan |
Thailand | Maharaj Nakorn Chiang Mai Hospital | Chiang mai | Muang |
Thailand | Prince of Songkla University | Hat Yai | Songkla |
United States | Johns Hopkins | Baltimore | Maryland |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Gabrail Cancer Center | Canton | Ohio |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | City of Hope | Duarte | California |
United States | Duke Cancer Institute | Durham | North Carolina |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Scripps | La Jolla | California |
United States | USC/Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Froedtert Hospital And Medical College | Milwaukee | Wisconsin |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Mount Sinai | New York | New York |
United States | University of California Irvine Division of Hematology-Oncology, Department of Medicine UC Irvine Health | Orange | California |
United States | Mayo Clinic of Arizona | Phoenix | Arizona |
United States | University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania |
United States | University of Rochester Medical Center | Rochester | New York |
United States | UC Davis | Sacramento | California |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Huntsman Cancer Institute | Salt Lake City | Utah |
United States | UT Health Cancer Center | San Antonio | Texas |
United States | UCLA - David Geffen School of Medicine | Santa Monica | California |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
United States | Virginia Mason | Seattle | Washington |
United States | University of Arizona | Tucson | Arizona |
United States | Lombardi Cancer Center, Georgetown University | Washington | District of Columbia |
United States | The Oncology Institute of Hope and Innovation | Whittier | California |
Lead Sponsor | Collaborator |
---|---|
Halozyme Therapeutics |
United States, Korea, Republic of, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Run-in Portion: Number of Participants With Adverse Events (AEs) | An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product (for example, study drug), whether or not considered related to the pharmaceutical product. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through 30 days after the end of treatment visit (maximum exposure: 508 days) | |
Primary | Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry) | Laboratory parameters evaluation included hematology (hemoglobin, hematocrit, red blood cell count, white blood cell [WBC] count, neutrophils [ANC], lymphocytes, monocytes, eosinophils, basophils, granulocytes, mean corpuscular hemoglobin, mean corpuscular volume, and platelet count) and blood chemistry (glucose, blood urea nitrogen [BUN], albumin, total bilirubin, alkaline phosphatase, aspartate aminotransferase [AST], alanine aminotransferase [ALT], electrolytes [including sodium, potassium, calcium, magnesium, chloride, and bicarbonate], and creatinine) evaluation. Clinical significance was defined as per Investigator's discretion. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days) | |
Primary | Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) and Vital Signs | Clinical significance of ECGs was defined as per Investigator's discretion. Assessment of vital signs was to include the measurement of blood pressure (systolic and diastolic), pulse, respiratory rate, and body temperature. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days) | |
Primary | Run-in Portion: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study Medication | Number of participants with AEs leading to dose reduction or interruption of any study medication (PEGPH20, CIS, GEM, or ATEZO) was reported. An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product (for example, study drug), whether or not considered related to the pharmaceutical product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days) | |
Primary | Expansion Portion: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1: Percentage of Participants With Objective Response | ORR was defined as percentage of participants who achieved either a complete response (CR) or partial response (PR). CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. | From date of randomization until the date of first documented progression of disease or date of death from any cause, whichever came first (maximum exposure: 421 days) | |
Secondary | Run-in Portion: ORR Based on RECIST v1.1: Percentage of Participants With Objective Response | ORR was defined as percentage of participants who achieved either a CR or PR. CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. | From date of randomization until the date of first documented progression of disease or date of death from any cause, whichever came first (maximum exposure: 508 days) | |
Secondary | Expansion Portion: Duration of Response (DOR) Based on RECIST v1.1 | DOR was considered the time from date of the first CR or PR until the date of first documentation of disease progression or date of death based on RECIST v1.1 for target lesions assessed by MRI/CT scans, as determined by independent radiologic review. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. | From date of the first CR or PR until the date of first documentation of disease progression or date of death, whichever came first (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Progression-Free Survival (PFS) Based on RECIST v1.1 | PFS was based on RECIST v1.1 for target lesions assessed by MRI/CT scans, as determined by independent radiologic review and was defined as the time from randomization to radiological disease progression or death. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on or prior to the current assessment (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of greater than or equal to (=) 5 mm. | From date of randomization until date of progressive disease or death from any cause, whichever came first (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Disease Control Rate (DCR) Based on RECIST v1.1: Percentage of Participants With CR, PR or Stable Disease (SD) | DCR was defined as the percentage of participants with CR, PR, or SD based on RECIST v1.1 for target lesions assessed by MRI/CT scans, as determined by independent radiologic review. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. | From date of randomization until date of progressive disease or death from any cause, whichever came first (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Overall Survival (OS) | Overall survival was defined as the time from randomization until death from any cause. | From randomization until death from any cause (maximum exposure: 421 days) | |
Secondary | Expansion Portion: OS by PD-L1 Expression Levels | Overall survival was defined as the time from randomization until death from any cause. | From randomization until death from any cause (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Number of Participants With AEs | An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product (for example, study drug), whether or not considered related to the pharmaceutical product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters (Hematology and Blood Chemistry) | Laboratory parameters evaluation included hematology (hemoglobin, hematocrit, red blood cell count, WBC count, neutrophils [ANC], lymphocytes, monocytes, eosinophils, basophils, granulocytes, mean corpuscular hemoglobin, mean corpuscular volume, and platelet count) and blood chemistry (glucose, BUN, albumin, total bilirubin, alkaline phosphatase, AST, ALT, electrolytes [including sodium, potassium, calcium, magnesium, chloride, and bicarbonate], and creatinine) evaluation. Clinical significance was defined as per Investigator's discretion. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 421 days) | |
Secondary | Expansion Portion: Number of Participants With Clinically Significant Abnormalities in ECG and Vital Signs | Clinical significance of ECGs was defined as per Investigator's discretion. Assessment of vital signs was to include the measurement of blood pressure (systolic and diastolic), pulse, respiratory rate, and body temperature. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through the end of treatment visit (maximum exposure: 421 days) | |
Secondary | Expansion Period: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study Medication | Number of participants with AEs leading to dose reduction or interruption of any study medication (PEGPH20, CIS, GEM, or ATEZO) was reported. An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product (for example, study drug), whether or not considered related to the pharmaceutical product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | From first exposure to study drug through 30 days after the end of treatment visit (maximum exposure: 421 days) | |
Secondary | Run-in and Expansion Portion : Maximum Observed Plasma Concentration (Cmax) of PEGPH20, ATEZO, GEM, and CIS | Plasma pharmacokinetic (PK) data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Cycle 1: multiple timepoints on Days 1, 2, 8, 9, 15; ATEZO: Day 1 of subsequent cycles and end of treatment (EOT) (maximum exposure: 508 days for run-in and 421 days for expansion); CIS and GEM: Cycle 1: multiple timepoints on Days 2,9 | |
Secondary | Run-in and Expansion Portion : Minimum Observed Plasma Concentration (Cmin) of PEGPH20 and ATEZO | PK data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Treatment Cycle 1: multiple timepoints on Days 1, 2, 8, 9, and 15; ATEZO: Day 1 of subsequent cycles and EOT visit (7 days after last 21-day cycle) (maximum exposure: 508 days for run-in portion and 421 days for expansion portion) | |
Secondary | Run-in and Expansion Portion : Elimination Rate Constant (Kel) of PEGPH20 | PK data were planned to be analyzed using a noncompartmental analysis approach. | Cycle 1: multiple timepoints on Days 1, 2, 8, 9, and 15 | |
Secondary | Run-in and Expansion Portion : Terminal Elimination Plasma Half-life (t1/2) of PEGPH20, ATEZO, GEM, and CIS | PK data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Cycle 1: multiple timepoints on Days 1, 2, 8, 9, 15; ATEZO: Day 1 of subsequent cycles and EOT visit (maximum exposure: 508 days for run-in and 421 days for expansion portion); CIS and GEM: Cycle 1: multiple timepoints on Days 2, 9 | |
Secondary | Run-in and Expansion Portion : Clearance (CL) of PEGPH20, ATEZO, GEM, and CIS | PK data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Cycle 1: multiple timepoints on Days 1, 2, 8, 9, 15; ATEZO: Day 1 of subsequent cycles and EOT visit (maximum exposure: 508 days for run-in and 421 days for expansion portion); CIS and GEM: Cycle 1: multiple timepoints on Days 2, 9 | |
Secondary | Run-in and Expansion Portion : Volume of Distribution (Vd) of PEGPH20, ATEZO, GEM, and CIS | PK data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Cycle 1: multiple timepoints on Days 1, 2, 8, 9, 15; ATEZO: Day 1 of subsequent cycles and EOT visit (maximum exposure: 508 days for run-in and 421 days for expansion portion); CIS and GEM: Cycle 1: multiple timepoints on Days 2, 9 | |
Secondary | Run-in and Expansion Portion: Area Under the Concentration Time Curve (AUC) of PEGPH20, ATEZO, GEM, and CIS | PK data were planned to be analyzed using a noncompartmental analysis approach. | PEGPH20 and ATEZO: Cycle 1: multiple timepoints on Days 1, 2, 8, 9, 15; ATEZO: Day 1 of subsequent cycles and EOT visit (maximum exposure: 508 days for run-in and 421 days for expansion portion); CIS and GEM: Cycle 1: multiple timepoints on Days 2, 9 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04077983 -
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04527679 -
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT04634058 -
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
|
Phase 2 | |
Active, not recruiting |
NCT03951597 -
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT03377179 -
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04361331 -
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT04072250 -
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
|
||
Recruiting |
NCT05210322 -
Percutaneous Cholangiopancreatoscopy Registry
|
||
Recruiting |
NCT04782804 -
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
|
Phase 1/Phase 2 | |
Recruiting |
NCT04264260 -
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
|
Phase 2 | |
Recruiting |
NCT06140134 -
Liver Transplantation in Intrahepatic Cholangiocarcinoma
|
||
Enrolling by invitation |
NCT04195503 -
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
|
N/A | |
Recruiting |
NCT04506281 -
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
|
Phase 2 | |
Recruiting |
NCT05124002 -
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
|
Phase 4 | |
Terminated |
NCT03316222 -
Study of GNS561 in Patients With Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03405909 -
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
|
||
Recruiting |
NCT06381648 -
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
|
||
Available |
NCT03414489 -
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
|